Glenmark Recalls Aprepitant Capsules Due to Missing Capsules in Blister Packs
Glenmark Pharmaceuticals is recalling 5,016 blister packs of Aprepitant 40 mg capsules because some packs are missing capsules.
The agency’s classification
FDA (Drugs): Class III
Class III is a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 1/5 (Low).
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The recall is classified as FDA Class III, which by definition is unlikely to cause adverse health consequences. The issue is a packaging defect (missing capsules) rather than a contamination or labeling error affecting safety.
Plain-English summary
Glenmark Pharmaceuticals Inc., USA is recalling 5,016 blister packs of Aprepitant Capsules, USP 40 mg. The recall is due to customer reports that some blister packs are missing capsules.
The affected product is Aprepitant Capsules, USP 40 mg, 1 capsule Unit Blister Pack, Rx Only. The specific lot number is 17180918 with an expiration date of June 2020. The product was distributed nationwide.
Consumers should check their blister packs for missing capsules. If a capsule is missing, they should contact their healthcare provider or pharmacist for guidance.
The recalled product
- Product
- APREPITANT (APREPITANT)
- Brand
- APREPITANT
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Category
- Drug — Prescription Drug
- Hazard
- Affected units
- 5,016
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot: 17180918
- EXP June 2020
UPCs (5)
- 0368462585764
- 0368462112335
- 0368462584767
- 0368462583401
- 368462583401
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · APREPITANT
- ModerateAprepitant 40 mg Prescription Drug Recalled for Manufacturing Temperature Deviations
FDA (Drugs) · 2022-06-15
Same manufacturer · Glenmark Pharmaceuticals Inc., USA
See all →- ModerateAzelaic Acid Gel 15% Recalled Over Grainy, Gritty, or Sandy Texture
FDA (Drugs) · 2026-08-05
- ModerateAlyacen 7/7/7 birth control tablets failed total impurities specification
FDA (Drugs) · 2026-06-24
- ModerateOndansetron tablets recalled because blister packs are not fully sealed
FDA (Drugs) · 2026-01-07
- CriticalFrozen chopped methi recalled after testing positive for Salmonella
FDA (Drugs) · 2025-12-17
- ModerateBisoprolol and hydrochlorothiazide tablets recalled over traces of another drug
FDA (Drugs) · 2025-12-10
Same hazard · packaging defect
See all →- HighEmbosphere Microspheres Recalled Due to Packaging Sterility Concerns
FDA (Devices) · 2026-10-07
- ModerateAmneal Recalls Estradiol Gel Packets Due to Empty or Partially Full Containers
FDA (Drugs) · 2026-10-07
- HighCardinal Health Recalls Presource Convenience Kits Due to Seal Defects
FDA (Devices) · 2026-09-30
- ModerateAVID Medical Recalls Halyard IV Start Kits Due to Packaging Seal Issues
FDA (Devices) · 2026-09-30
- HighCardinal Health Recalls Presource Convenience Kits Due to Potential Seal Defects
FDA (Devices) · 2026-09-30
Similar recalls
- HighAtomoxetine Capsules Recalled for Manufacturing Impurity Above Limits
FDA (Drugs) · 2025-02-26
- HighAtomoxetine capsules recalled due to elevated N-nitroso impurity
FDA (Drugs) · 2025-02-26
- HighAtomoxetine Capsules Recalled Due to Excess N-Nitroso Impurity
FDA (Drugs) · 2025-02-26
- HighAtomoxetine Capsules Recalled Due to N-Nitroso Impurity Contamination
FDA (Drugs) · 2025-02-26
- HighAtomoxetine 80 mg Capsules Recalled for N-Nitroso Impurity Contamination
FDA (Drugs) · 2025-02-26
- ModerateGlenmark Pharmaceuticals Recalls Telmisartan/Hydrochlorothiazide Due to Defective Blister Packs
FDA (Drugs) · 2022-08-17